1. Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a rand...
KEYNOTE-355研究是继IMpassion130研究[1]后第二个大型Ⅲ 期随机对照临床研究, 证实免疫治疗联合化疗在晚期三阴性乳腺癌一线治疗中的疗效。基于该研究统计设计合理、方案可行性强, 结论可靠, 2021 V4版美国综合肿瘤网络(national comprehensive...
三阴性帕博利珠单抗一线治疗1文献来源Cortes J,Cescon DW,Rugo HS,et al.Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triplenegative breast cancer(KEYNOTE355):A randomised,placebocontrolled,doubleblind,phase 3 clinical trial[...
Of 1,372 patientsscreened in the KEYNOTE-355 trial, 847 were randomly assigned to treatment: 566 to the pembrolizumab/chemotherapy group and 281 to the placebo/chemotherapy group. Chemotherapy options included nab-paclitaxel, paclitaxel, gemcitabine, and carboplatin. Patient...
In KEYNOTE-355, when KEYTRUDA and chemotherapy (paclitaxel, paclitaxel protein-bound, or gemcitabine and carboplatin) were administered to patients with locally recurrent unresectable or metastatic TNBC who had not been previously treated with chemotherapy in the metastatic setting (n=596...
In KEYNOTE-355, when KEYTRUDA and chemotherapy (paclitaxel, paclitaxel protein-bound, or gemcitabine and carboplatin) were administered to patients with locally recurrent unresectable or metastatic TNBC who had not been previously treated with chemotherapy in the metastatic setting (n=596...
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Su...
In KEYNOTE-355, when KEYTRUDA and chemotherapy (paclitaxel, paclitaxel protein-bound, or gemcitabine and carboplatin) were administered to patients with locally recurrent unresectable or metastatic TNBC who had not been previously treated with ...
KEYNOTE-355研究是继IMpassion130研究[1]后第二个大型Ⅲ 期随机对照临床研究, 证实免疫治疗联合化疗在晚期三阴性乳腺癌一线治疗中的疗效。基于该研究统计设计合理、方案可行性强, 结论可靠, 2021 V4版美国综合肿瘤网络(national comprehensive cancer network, NCCN)乳腺癌诊疗指南将帕博利珠单抗联合化疗方案作为晚期三阴...
In Pivotal Phase 3 KEYNOTE-355 Study, KEYTRUDA Plus Chemotherapy Significantly Improved PFS Compared to Chemotherapy Alone in Patients with mTNBC Whose Tumors Expressed PD-L1 (CPS ≥10) Based on the recommendation of the DMC, the trial will continue without changes to evaluate the other dual prim...